Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Dry Eye Disease

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has enrolled the first patient into a Phase 2 clinical trial o...

Related Keywords

United States ,Chris Lewis ,Thomas Burns ,Exchange Commission ,Glaukos Corporation ,Investor Relations Corporate Strategy Development ,Dry Eye Disease ,Eye Disease ,Micro Invasive Glaucoma Surgery ,Quarterly Report ,Investor Section ,Investor Relations ,Corporate Strategy ,